Clinical Trial Update: A Randomized Study of SPK-10001 Gene Therapy in Participants With Huntington's Disease [Phase 1, Phase 2]

View source ↗

Summary

This document reports a randomized Phase 1/2 trial of SPK-10001 gene therapy for Huntington's disease, with participant recruitment underway.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Huntington Disease

Drugs mentioned

• SPK-10001

Snippet

Sponsor: Hoffmann-La Roche | Conditions: Huntington Disease | Phase 1, Phase 2 | Status: RECRUITING